Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models by Bility, Moses T et al.
Liver immune-pathogenesis and therapy of human liver tropic
virus infection in humanized mouse models
Moses T Bility, Feng Li, Liang Cheng, and Lishan Su
Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, School
of Medicine, The University of North Carolina, Chapel Hill, North Carolina, USA
Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infect and replicate primarily in human
hepatocytes. Few reliable and easy accessible animal models are available for studying the
immune system’s contribution to the liver disease progression during hepatitis virus infection.
Humanized mouse models reconstituted with human hematopoietic stem cells (HSCs) have been
developed to study human immunology, human immunodeficiency virus 1 infection, and
immunopathogenesis. However, a humanized mouse model engrafted with both human immune
and human liver cells is needed to study infection and immunopathogenesis of HBV/HCV
infection in vivo. We have recently developed the humanized mouse model with both human
immune and human liver cells (AFC8-hu HSC/Hep) to study immunopathogenesis and therapy of
HCV infection in vivo. In this review, we summarize the current models of HBV/HCV infection
and their limitations in immunopathogenesis. We will then present our recent findings of HCV
infection and immunopathogenesis in the AFC8-hu HSC/Hep mouse, which supports HCV
infection, human T-cell response and associated liver pathogenesis. Inoculation of humanized
mice with primary HCV isolates resulted in long-term HCV infection. HCV infection induced
elevated infiltration of human immune cells in the livers of HCV-infected humanized mice. HCV
infection also induced HCV-specific T-cell immune response in lymphoid tissues of humanized
mice. Additionally, HCV infection induced liver fibrosis in humanized mice. Anti-human alpha
smooth muscle actin (αSMA) staining showed elevated human hepatic stellate cell activation in
HCV-infected humanized mice. We discuss the limitation and future improvements of the AFC8-
hu HSC/Hep mouse model and its application in evaluating novel therapeutics, as well as studying
both HCV and HBV infection, human immune responses, and associated human liver fibrosis and
cancer.
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Approximately 500 million people are chronically infected with hepatitis B and C viruses
(HBV/HCV), progressively resulting in fibrosis/cirrhosis of the liver and development of
hepatocellular carcinoma (HCC) over several decades.1,2 Chronic HBV/HCV infection is
associated with impaired immune responses to viral antigens and liver inflammation, leading
to the liver diseases.3,4 Because of the lack of robust animal models, very little is known
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about how HBV/HCV evades host immunity to establish chronic infection.5-7 Furthermore,
very little is known about the mechanisms of HBV/HCV-induced liver fibrosis and HCC.
HBV and HCV have host species restriction, namely humans and chimpanzees. To
overcome host species restriction barrier for in vivo infection and disease modeling, several
small-animal models of hepatitis virus-transgenic mouse and surrogate hepatitis virus have
been employed to delineate the mechanisms of chronic infection and liver disease. More
recently, human-murine chimeric liver models have been developed for studying in vivo
infection and evaluating therapeutics.8 This strategy was further advanced by the recent
development of humanized mice with both human hepatocytes and immune cells, which
enabled both hepatitis virus infection and liver immunopathogenesis.9,10 We will focus on
the update of mouse models for studying HBV/HCV infection, immunopathogenesis, and
liver diseases.
Transgenic mouse models of human hepatitis viruses
Transgenic mice expressing whole genome or individual genes of HBV have been widely
used to investigate the mechanism of HBV replication, gene expression, and
immunopathogenesis of HBV in a small-animal model.11-15 The immune system of the mice
is tolerant to the viral antigen, and therefore, most of the mice do not develop liver disease.
Nonetheless, adoptive transfer of HBV-specific cytotoxic T lymphocytes (CTLs) or spleen
cells from syngeneic mice provides a way for immunological study.
HBV-transgenic mice with 1.3× of HBV genome can produce high level of infectious viral
particles.13 The viral particles produced in the mice are morphologically indistinguishable
from virus derived from human, and they are infectious when inoculated in chimpanzees.16
No liver disease developed in these mice, suggesting that HBV was not directly
cytopathic.13 This transgenic mouse model was used to test the efficacy of HBV inhibitors,
including nucleoside analogs reverse transcriptase inhibitors, cytokines, and small
interfering RNAs.17-20 By adoptive transfer of hepatitis B surface antigen (HBsAg)-specific
CTLs into HBV-transgenic mice, people found that CTLs can inhibit HBV DNA replication
by noncytolytic mechanisms via release of cytokines.21 Transfer of HBsAg-specific CTLs
into the mice can also lead to liver injury, and antigen-non-specific inflammatory cells
recruited into the liver during the process can amplify the severity of liver damage.22 Using
HBV-transgenic severe combined immunodeficient (SCID) mice, Larkin et al. report that
the mice clear the HBV virus from the serum and develop chronic liver disease after
adoptive transfer of syngeneic splenocytes.23 Report also shows that a subset of nonclassical
natural killer T cells mediates acute hepatitis after transfer of splenocytes into the HBV-
transgenic mice on the recombination activating gene (RAG)–/– or T-cell receptor (TCR)-
α–/– background.24
The development of transgenic mice expressing individual genes of HBV allowed
investigators to explore the role of certain viral proteins in vivo. Transgenic mice that
overexpress HBsAg along with pre-S polypeptide accumulate the surface antigen in the
endoplasmic reticulum (ER). These mice display low levels of hepatocellular injury and can
eventually progressed to HCC.25 HCC also develop in mice that expressed high levels of the
HBV X antigen (HBx) in the liver.14 Experiments with HBx transgenic mice reveal that the
X protein can impair the function of p53.26
As in the study of HBV, transgenic mice expressing HCV proteins either individually or
together as a polyprotein have been developed to study the effect of these proteins on liver
pathology. Hepatic steatosis is a common histological feature of chronic hepatitis C. The
same phenomenon is also observed in the HCV core protein transgenic mice.27 The liver of
HCV core transgenic mice showed resistance to concanavalin A-induced injury, which
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indicated that core protein may protect HCV-infected liver cells from destruction by the
immune system.28 Transgenic expression of HCV core protein in the mouse liver can lead to
the development of HCCs,29 and transgenic mice harboring complete HCV polyprotein
showed an increased risk of liver cancer that suggested that other HCV proteins might also
play a role in the induction of HCCs.30 However, expression of HCV nonstructural proteins
did not cause any spontaneous liver pathology.31,32 To overcome the immune tolerance
status to HCV antigen in transgenic mice and investigate the immune response to HCV in
vivo, people use the Cre-loxP recombination system to make inducible HCV protein
expression transgenic mice. An anti-HCV core antibody response and an HCV-specific T-
cell response were observed in the transgenic mice after induction of core transgene
expression, resulting in hepatitis or liver inflammation.33,34
The HBV and HCV transgenic mouse models significantly contribute to our understanding
of virus–host interaction in vivo. However, these models have important limitations.
Because the mouse liver cannot be infected with HBV or HCV, we cannot study the viral
entry and spread, and no covalently closed circular DNA is produced in the HBV-transgenic
mice. More important, HBV or HCV proteins are expressed as self-antigens; thus, it is not
possible to study host immune response in the pathogenesis process. To overcome these
limitations, chimeric mice repopulated with either human hepatocytes alone or with both
human hepatocytes and immune system are needed to study HBV/HCV infection and
immunopathogensis.
Human-murine chimeric liver models
Currently, several types of mouse models engrafted with human hepatocytes have been
established for supporting HBV/HCV infection and replication. The first reported (and also
the most widely used) is the albumin (Alb)-urokinase plasminogen activator (uPA)
transgenic immune-deficient mice (C.b-17/SCID/bg8 and RAG2–/– mice35) in which the
uPA gene is under control of the albumin promoter. The homozygous uPA-SCID mouse
overexpresses uPA in the liver, resulting in a profoundly hypofibrinogenemic state and
leading to hepatocyte death. Adult human hepatocytes are intrasplenically transplanted into
newborn homozygous uPA-SCID mice. The chimeric liver with high levels (up to 90%) of
human hepatocytes supports efficient infection of HBV36,37 and HCV.8 Alb-uPA mice,
therefore, provide an invaluable tool for studying HBV/HCV infection and for screening and
evaluating antiviral therapeutics. Because of the immunodeficiency of these mice, however,
neither pathogen- nor vaccine-induced immune responses can be studied, and most of the
studies have focused on testing antiviral drugs. In addition, the homozygous Alb-uPA mice
have a high neonatal mortality rate because of severe hemorrhage, and the survived mice
also have a short lifespan after transplantation (death rate around 40% in a large cohort
study38), which also limits the wide application of these mice.
The second type of chimeric human-mouse liver model uses the fumaryl acetoacetate
hydrolase (Fah)/RAG2/interleukin (IL) 2-gammaC (FRG) triple mutant mice.39,40 Mutation
of Fah results in the hepatic accumulation of toxic tyrosine metabolic intermediates and,
thereafter, the death of mouse hepatocytes. Compared with the Alb-uPA mice, the FRG
mice have a major advantage, in that the extent of liver injury can be controlled by
administering and withdrawing 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione
(NTBC).40 The humanized FRG mice can support robust HBV and HCV replication, and
high HCV titers were detected in the blood. Third, the herpes simplex virus (HSV)
thymidine kinase (TK) was used in non-obese diabetic (NOD)-SCID transgenic mice, with
the HSV-TK under control of the hepatic specific Alb promoter.41 Administration of
gancyclovir will lead to specific mouse hepatocyte depletion and can lead to efficient
engraftment of human hepatocytes.
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Another human-mouse liver model for supporting HBV/HCV infection is the ectopic
transplantation of human liver tissue under the kidney capsule.42,43 However, the HBV and
HCV titer is relatively low in the blood, and the duration of infection is limited because of
the short-lived transplanted liver tissues.
Humanized mouse models with both human liver and immune cells
The earlier human-murine chimeric liver mouse models support robust HBV/HCV
replication. However, these models lack a functional immune system; thus, it is not possible
to study host immune response and hepatitis virus-induced immunopathology.8,40
Furthermore, because of the constitutively liver toxic transgene (uPA) or mutation (Fah), the
poor health of uPA- or Fah-based mice humanized liver has significantly limited their
general use. To overcome the problems associated with current chimeric human-murine
liver mouse models, we recently developed a novel humanized mouse model (AFC8
humanized mouse model) with both human immune and liver cells.10,44 The AFC8 mouse is
derived from the Balb/C-RAG2-γC-null immunodeficient mouse (double knockout [DKO])
carrying a liver-specific transgene with inducible suicidal activity. The AFC8 mouse
supports development of a functional human immune system and liver cells following
intrahepatic injection of human CD34+ hematopoietic stem cells (HSCs) and human liver
progenitor cells (Hep) obtained from fetal liver tissue.10 AFC8-hu HSC/Hep mice supported
HCV infection in the liver and generated anti-HCV human T-cell response. Additionally,
HCV infection induced hepatitis and liver fibrosis, which correlated with activation of
human hepatic stellate cells and expression of human fibrogenic genes (Fig. 1 and Washburn
et al.10). The mechanism of human-specific fibrosis induction in the chimeric liver is not
clear. The AFC8-hu mouse provides an excellent model to study how HCV or HBV
infection induces human liver fibrosis in vivo.
Perspectives
The humanized AFC8 mouse is the first and only in vivo small animal model to recapitulate
HCV infection, immune responses, and its associated liver disease, as observed in humans.
It also supports infection of both HCV and human immunodeficiency virus (HIV) 1.
Because HIV-1 coinfection has been reported to significantly exacerbate HCV-related liver
diseases, the AFC8-hu HSC/Hep mouse allows investigation of HCV and HIV-1 coinfection
in vivo.45,46 However, the human liver engraftment in the current AFC8-hu mice (~15%) is
relatively low. It is difficult to support significant replication of HCV to show detectable
viremia in the blood. Thus, it is important to improve it, either by more efficient depletion of
mouse liver cells or by enhancing human liver cell proliferation and survival, to support
efficient HCV infection. HBV infection is more efficient in other humanized mouse models
with chimeric human liver. Consistently, long-term HBV infection is supported in AFC8-hu
HSC/Hep mice, associated with similar immunopathogenesis and liver diseases (Bility and
Su, unpubl. data, 2012). It is thus critical that the current AFC8-hu mouse model is
improved that will support robust HBV/HCV infection, immunopathogenesis, and liver
diseases, including fibrosis, cirrhosis, and cancer. The models will play a critical role in
elucidating immune mechanisms of HBV/HCV-induced liver diseases, as well as in
developing novel therapeutic strategies to treat HBV/HCV infection.
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AFC8-hu Hep/hematopoietic stem cell (HSC) mice support engraftment of human immune/
liver cells and hepatitis C virus (HCV) infection. (a) Inducible activation of caspase 8
through dimerization of FK506-binding protein (FKBP)-caspase 8. The chemical dimerizer
AP20187 leads to activation of caspase 8 and apoptosis. (b) Mouse liver injury can be
repeatedly induced in AFC8 transgenic mice. AFC8 or littermate control mice were injected
with AP20187 at day 0 and day 6. ALT was measured in serum at −1, 0, 1, 3, 6, and 7 days
postdrug treatment. Data represent means ± SD, P < 0.05. ( ) Control; ( ) APC8;
( ) APC8 no drug. (c) Construction of AFC8-hu HSC/Hep mice with human CD34+
HSC and EpCAM+ hematoblasts. (d) Lymphoid organs including thymus, spleen, and
lymph node (LN) are shown to demonstrate human immune cell reconstitution (top). Liver
sections from control mice without transplant (left) and both control (middle) and AFC8
(right) transplanted with human HSC/Hep (AFC8-hu HSC/Hep) were stained with
antihuman albumin antibody. Human albumin positive cells are shown (Middle). AFC8-hu
HSC/Hep mice develop liver fibrosis after HCV infection (bottom). Liver sections from
AFC8/mock, AFC8-hu/mock, and AFC8-hu/HCV mice were stained with sirius red/fast
green to visualize liver fibrosis (red).
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